FIELD: biotechnology.
SUBSTANCE: present invention relates to compositions based on a conjugate of an oxyntomodulin derivative, and can be used in medicine to reduce blood lipids in preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis. Oxyntomodulin derivative with SEQ ID NO: 28, 32–34, fused with Fc-region of immunoglobulin through non-peptidyl polymer, which covalently binds derivative of oxyntomodulin and Fc-region of immunoglobulin.
EFFECT: invention enables to obtain a conjugate of an oxyntomodulin derivative, having high ability to activate GLP-1 receptor and glucagon receptor in comparison with natural oxyntomodulin and allowing to effectively reduce the levels of total cholesterol, low-density cholesterol and triglycerides in the blood, which were increased due to a high-fat diet, and increase high-density cholesterol levels and high-density/low-density cholesterol ratio.
16 cl, 10 dwg, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
